
Addressing Unmet Needs with Emerging MG Therapies
The next generation of MG treatment may depend on combining rapid symptom control with upstream strategies designed to produce deeper and more sustained immune effects. Supported by Vor Bio Medical Affairs.
Episodes in this series

In this episode, ‘Addressing Unmet Needs with Emerging MG Therapies,’ the panelists explore which developing therapeutic strategies may have the greatest potential to improve future MG care. Expert faculty consider B-cell–directed therapies, CD19, CD20, CD38, BCMA, CAR-T approaches, signaling inhibitors, and other emerging mechanisms.
One strategy discussed is the rational combination of upstream and downstream therapy. Panelists describe a model in which rapidly acting downstream agents could provide early disease control while upstream therapies work toward more sustained suppression of pathogenic immune activity. The experts emphasize that the long-term value of upstream approaches will depend not only on the depth and durability of efficacy but also on sustained safety.
CAR-T therapy is discussed as an example of a potentially highly durable approach that carries substantial logistical and safety considerations. The panel cautions that a limited-treatment strategy is only advantageous if clinical benefit is sufficiently prolonged to justify its upfront burden and potential complications.
The faculty also discusses antigen-specific tolerance as an emerging concept that could theoretically reduce dependence on broad immunomodulation or immunosuppression. While early preclinical findings are described as intriguing, panelists emphasize that animal models do not necessarily predict human MG outcomes.
The discussion concludes with the concept of immune reset. Rather than requiring complete elimination of disease, faculty suggest that a meaningful therapeutic advance could involve shifting MG toward a milder, more manageable state requiring less ongoing therapy. The timing and intensity of early treatment and whether disease course can ultimately be altered remain key unanswered questions.
The next episode in this series, ‘Defining Treatment Success in MG,’ features the panelists discussing how to establish short- and long-term goals, define treatment success, and reassess expectations as patients respond to therapy.
Related to this article








